Related references
Note: Only part of the references are listed.Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy
Wenbo Han et al.
BIOMATERIALS (2022)
Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
TGFβ biology in cancer progression and immunotherapy
Rik Derynck et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Samuel A. Jacobs et al.
CLINICAL CANCER RESEARCH (2021)
Cell death pathways: intricate connections and disease implications
Matthias Kist et al.
EMBO JOURNAL (2021)
Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer
Weiqiang Lu et al.
EMBO MOLECULAR MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Bin Yang et al.
CANCER RESEARCH (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ganoderma lucidum Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis
Ming Song et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2021)
Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer
Jiawen Yang et al.
CELL DEATH & DISEASE (2021)
Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin (vol 13, pg 13515, 2020)
Changshun Yang et al.
AGING-US (2021)
A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Keigo Chida et al.
CLINICAL CANCER RESEARCH (2021)
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma et al.
CANCER DISCOVERY (2021)
Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer
Nazia Chaudhary et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
STAT1 Is Required for Decreasing Accumulation of Granulocytic Cells via IL-17 during Initial Steps of Colitis-Associated Cancer
Yael Delgado-Ramirez et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer
Aldona Kasprzak
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Dennis Doleschel et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation
Fuqing Hu et al.
NATURE COMMUNICATIONS (2021)
Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
Degao Chen et al.
THERANOSTICS (2021)
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer
Ming-Fang Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Mutations and mechanisms of WNT pathway tumour suppressors in cancer
Jeroen M. Bugter et al.
NATURE REVIEWS CANCER (2021)
In search of definitions: Cancer-associated fibroblasts and their markers
Martin Nurmik et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells
Xuan Deng et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin
Xuefei Zhang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Sona Vodenkova et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Responsive Exosome Nano-bioconjugates for Synergistic Cancer Therapy
Weidong Nie et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
SNHG14 stimulates cell autophagy to facilitate cisplatin resistance of colorectal cancer by regulating miR-186/ATG14 axis
Yi Han et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages
Zhipeng Liu et al.
CANCER LETTERS (2020)
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors
Kirsty Ford et al.
CANCER RESEARCH (2020)
The role of JAK/STAT signaling pathway and its inhibitors in diseases
Ping Xin et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Tumor-associated macrophages
Luca Cassetta et al.
CURRENT BIOLOGY (2020)
LncRNA NEAT1 knockdown attenuates autophagy to elevate 5-FU sensitivity in colorectal cancer via targeting miR-34a
Fen Liu et al.
CANCER MEDICINE (2020)
Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes
Sixue Bi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2020)
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
Jean-Pierre Delord et al.
INVESTIGATIONAL NEW DRUGS (2020)
Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer
Yann Kieffer et al.
CANCER DISCOVERY (2020)
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Davis Y. Torrejon et al.
CANCER DISCOVERY (2020)
Role of Wnt/β-Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer
Shengli Yuan et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy
Muhammad Zaeem Noman et al.
SCIENCE ADVANCES (2020)
Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer
Chang-Soo Hong et al.
CANCER SCIENCE (2020)
5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes
Sabrina Blondy et al.
CANCER SCIENCE (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Hua Ye et al.
CELL COMMUNICATION AND SIGNALING (2020)
Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Mateusz Kciuk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
Qing-Hai Li et al.
GASTROENTEROLOGY REPORT (2020)
Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
Michael Fichtner et al.
CELL DEATH & DISEASE (2020)
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack et al.
FRONTIERS IN IMMUNOLOGY (2020)
Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation
Peng Chen et al.
THERANOSTICS (2020)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145
Rongrong Gao et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2019)
Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells
Mingshui Chen et al.
BMC CANCER (2019)
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
Wenting Liao et al.
CANCER CELL (2019)
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Lorenza Rimassa et al.
CLINICAL COLORECTAL CANCER (2019)
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Yanhua Mou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
BCL-2 family isoforms in apoptosis and cancer
Chloe F. A. Warren et al.
CELL DEATH & DISEASE (2019)
The current state of molecular testing in the treatment of patients with solid tumors, 2019
Wafik S. El-Deiry et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Natalia Guillen Diaz-Maroto et al.
CLINICAL CANCER RESEARCH (2019)
Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer
Qingyang Feng et al.
CLINICAL CANCER RESEARCH (2019)
CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer
J. L. Hu et al.
MOLECULAR CANCER (2019)
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Weimin Wang et al.
NATURE (2019)
EGFR is required for Wnt9a-Fzd9b signalling specificity in haematopoietic stem cells
Stephanie Grainger et al.
NATURE CELL BIOLOGY (2019)
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Andrew Woolston et al.
CANCER CELL (2019)
TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression
Shiyan Wang et al.
CANCER RESEARCH (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling
Qiuying Quan et al.
ONCOLOGY RESEARCH (2019)
IFN-γ: A cytokine at the right time, is in the right place
J. Daniel Burke et al.
SEMINARS IN IMMUNOLOGY (2019)
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
Xiaopin Duan et al.
NATURE COMMUNICATIONS (2019)
LncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells
Xinke Wang et al.
CANCER CELL INTERNATIONAL (2019)
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
Jeffrey Melson Clarke et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
Barry A. Kriegsman et al.
JOURNAL OF IMMUNOLOGY (2019)
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Shigehiro Koganemaru et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Autophagy-related Proteins as a Prognostic Factor of Patients With Colorectal Cancer
Evangelos Koustas et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
533PDBACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
N B Mettu et al.
ANNALS OF ONCOLOGY (2019)
circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637
Yanli Zhang et al.
EBIOMEDICINE (2019)
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers
Chang Gon Kim et al.
SCIENCE IMMUNOLOGY (2019)
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
S. Napolitano et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Autophagy in the renewal, differentiation and homeostasis of immune cells
Alexander J. Clarke et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Christopher J. Hanley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance
Atrish Bagchi et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Christopher J. Hanley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Knockdown of aquaporin-5 sensitizes colorectal cancer cells to 5-fluorouracil via inhibition of the Wnt-beta-catenin signaling pathway
Qing Li et al.
BIOCHEMISTRY AND CELL BIOLOGY (2018)
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer
Chen Shaojun et al.
CANCER BIOLOGY & THERAPY (2018)
IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)
Jing Du et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function
Andrew Stiff et al.
CLINICAL CANCER RESEARCH (2018)
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Femke M. de Man et al.
CLINICAL PHARMACOKINETICS (2018)
Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer
Rong Yang et al.
IMMUNOLOGY (2018)
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Jonathan M. Loree et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Knockdown of long non-coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells
Heng Fan et al.
MOLECULAR MEDICINE REPORTS (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
DKK2 imparts tumor immunity evasion through beta-catenin-independent suppression of cytotoxic immune-cell activation
Qian Xiao et al.
NATURE MEDICINE (2018)
Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer
Yen-An Tang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso et al.
CANCER DISCOVERY (2018)
Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19
Jing Ren et al.
THERANOSTICS (2018)
Participation of CCL1 in Snail-Positive Fibroblasts in Colorectal Cancer Contribute to 5-Fluorouracil/Paclitaxel Chemoresistance
Ziqian Li et al.
CANCER RESEARCH AND TREATMENT (2018)
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Jonathan M. Loree et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Hydrogen Sulfide Reduces Myeloid-Derived Suppressor Cell-Mediated Inflammatory Response in a Model of Helicobacter hepaticus-Induced Colitis
Paola De Cicco et al.
FRONTIERS IN IMMUNOLOGY (2018)
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer
Jenny F. Seligmann et al.
JAMA ONCOLOGY (2018)
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial
Clara Montagut et al.
JAMA ONCOLOGY (2018)
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
Giulia Fornasier et al.
ADVANCES IN THERAPY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Pan-cancer deconvolution of tumour composition using DNA methylation
Ankur Chakravarthy et al.
NATURE COMMUNICATIONS (2018)
Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance
Yuki Nakanishi et al.
IMMUNITY (2018)
Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy
Meng Wang et al.
CELL DEATH & DISEASE (2018)
Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
George A. Dominguez et al.
CLINICAL CANCER RESEARCH (2017)
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
CLINICAL CANCER RESEARCH (2017)
53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway
Jing Yao et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC)
Howard S. Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression
Andrew J. Garton et al.
MOLECULAR CANCER THERAPEUTICS (2017)
PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K
Mouhannad Malek et al.
MOLECULAR CELL (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
IncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling
Yuanyuan Lu et al.
NATURE MEDICINE (2017)
Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin
Zeting Yuan et al.
ONCOLOGY REPORTS (2017)
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
Robin M. J. M. van Geel et al.
CANCER DISCOVERY (2017)
Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer
Alberto Malesci et al.
ONCOIMMUNOLOGY (2017)
The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
Yuan Yin et al.
CLINICAL CANCER RESEARCH (2017)
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
Eiji Shinozaki et al.
BRITISH JOURNAL OF CANCER (2017)
Targeting autophagy in cancer
Jean M. Mulcahy Levy et al.
NATURE REVIEWS CANCER (2017)
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend et al.
CANCER RESEARCH (2017)
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
TaChung Yu et al.
CELL (2017)
miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression
Hui Zhou et al.
CELL PROLIFERATION (2017)
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
Vivek Subbiah et al.
JCI INSIGHT (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model
Chenbo Ding et al.
BMC CANCER (2016)
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
E. Elez et al.
BRITISH JOURNAL OF CANCER (2016)
Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine
Xuan Zhang et al.
CANCER LETTERS (2016)
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Francisco J. Sanchez-Martin et al.
CLINICAL CANCER RESEARCH (2016)
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma
Daniel W. Bowles et al.
CLINICAL COLORECTAL CANCER (2016)
The untold story of IFN-γ in cancer biology
M. Alper Kursunel et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2016)
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
Wen Li et al.
DRUG RESISTANCE UPDATES (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
Cathy Eng et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity
Caroline Baer et al.
NATURE CELL BIOLOGY (2016)
Mechanisms and regulation of endothelial VEGF receptor signalling
Michael Simons et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Beth O. van Emburgh et al.
NATURE COMMUNICATIONS (2016)
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Vincenzo Bronte et al.
NATURE COMMUNICATIONS (2016)
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer
Filippo Pietrantonio et al.
CANCER DISCOVERY (2016)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S. Hong et al.
CANCER DISCOVERY (2016)
Tumor-specific gene therapy for pancreatic cancer using human neural stem cells encoding carboxylesterase
Sung S. Choi et al.
ONCOTARGET (2016)
The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells
Gabriele Romano et al.
ONCOTARGET (2016)
Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients
Salman M. Toor et al.
FRONTIERS IN IMMUNOLOGY (2016)
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer
Jenny F. Seligmann et al.
JAMA ONCOLOGY (2016)
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena et al.
CLINICAL CANCER RESEARCH (2015)
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Rona Yaeger et al.
CLINICAL CANCER RESEARCH (2015)
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models
Teresa Troiani et al.
CLINICAL CANCER RESEARCH (2015)
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Stefania Napolitano et al.
CLINICAL CANCER RESEARCH (2015)
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
Dejan Juric et al.
CLINICAL CANCER RESEARCH (2015)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
Host effects contributing to cancer therapy resistance
Ofrat Beyar Katz et al.
DRUG RESISTANCE UPDATES (2015)
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
C. Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2015)
Targeting autophagy to overcome drug resistance in cancer therapy
Ankit Kumar et al.
FUTURE MEDICINAL CHEMISTRY (2015)
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
Hsin-Wei Liao et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.
Christopher Hanyoung Lieu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
Francesco Sclafani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti et al.
NATURE (2015)
SLC transporters as therapeutic targets: emerging opportunities
Lawrence Lin et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Eugenia R. Zanella et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer
Y. Zhang et al.
CELL DEATH & DISEASE (2015)
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Rodrigo Dienstmann et al.
CANCER DISCOVERY (2015)
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Shyam M. Kavuri et al.
CANCER DISCOVERY (2015)
CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function
Eunyoung Chun et al.
CELL REPORTS (2015)
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
Francesco Sclafani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Inhibition of Transient Receptor Potential Channel 5 Reverses 5-Fluorouracil Resistance in Human Colorectal Cancer Cells
Teng Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer
Qiong Li et al.
SCIENTIFIC REPORTS (2015)
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
H. Blons et al.
ANNALS OF ONCOLOGY (2014)
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F. Ciardiello et al.
ANNALS OF ONCOLOGY (2014)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells
T. Luca et al.
CELL PROLIFERATION (2014)
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem et al.
CLINICAL CANCER RESEARCH (2014)
Old Drug New Use-Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
Ren Kong et al.
CLINICAL CANCER RESEARCH (2014)
γδT17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer
Pin Wu et al.
IMMUNITY (2014)
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo
Melanie Spitzner et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis
Thomas Condamine et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction
Ying Wu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza
Tao Hu et al.
PHYTOMEDICINE (2014)
Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides
Yu-Li Lo et al.
PLOS ONE (2014)
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
Sandra Misale et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
Fotios Loupakis et al.
TARGETED ONCOLOGY (2014)
CSF-1 Receptor Signaling in Myeloid Cells
E. Richard Stanley et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation
K. A. Kang et al.
CELL DEATH & DISEASE (2014)
Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer
R. C. Turkington et al.
CELL DEATH & DISEASE (2014)
Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice
Bo-Rim Yi et al.
ONCOTARGET (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
Laura J. Vella et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma
Abolfazl Akbari et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer
Elinor Bexe Lindskog et al.
BMC CLINICAL PATHOLOGY (2014)
Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells
Cindy R. Timme et al.
APOPTOSIS (2013)
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
Matthew J. Sale et al.
BIOCHEMICAL JOURNAL (2013)
Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo
Yu-Li Lo et al.
BIOMEDICINE & PHARMACOTHERAPY (2013)
Oncogenic ERBB3 Mutations in Human Cancers
Bijay S. Jaiswal et al.
CANCER CELL (2013)
CXCR2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis
Hiroshi Katoh et al.
CANCER CELL (2013)
FGFR4 Promotes Stroma-Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer
Rui Liu et al.
CANCER RESEARCH (2013)
TGF-β An emerging player in drug resistance
Diede Brunen et al.
CELL CYCLE (2013)
Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Teresa Troiani et al.
CLINICAL CANCER RESEARCH (2013)
Manipulation of autophagy in cancer cells: an innovative strategy to fight drug resistance
Francesca Aredia et al.
FUTURE MEDICINAL CHEMISTRY (2013)
Canonical Wnt Signaling Negatively Modulates Regulatory T Cell Function
Jorg van Loosdregt et al.
IMMUNITY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A
Fiorenza Lotti et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08
Kay Pogue-Geile et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
Minmin Song et al.
PLOS ONE (2013)
Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer
M. Griffith et al.
PHARMACOGENOMICS JOURNAL (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
The tumor microenvironment: a pitch for multiple players
Giovanna Schiavoni et al.
FRONTIERS IN ONCOLOGY (2013)
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
C. Mao et al.
ANNALS OF ONCOLOGY (2012)
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab
M. Scartozzi et al.
ANNALS OF ONCOLOGY (2012)
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Sidong Huang et al.
CELL (2012)
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Scott J. Dixon et al.
CELL (2012)
Macrophages in Tumor Microenvironments and the Progression of Tumors
Ning-Bo Hao et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
A. Palmeira et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms
Jamal Joudeh et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Cisplatin-Induced Chemoresistance in Colon Cancer Cells Involves FXR-Dependent and FXR-independent Up-Regulation of ABC Proteins
Elisa Herraez et al.
MOLECULAR PHARMACEUTICS (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Targeting IAP proteins for therapeutic intervention in cancer
Simone Fulda et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Wnt Signaling in Cancer
Paul Polakis
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines
Zhen Liu et al.
Chinese Journal of Cancer (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
ALK1 as an emerging target for antiangiogenic therapy of cancer
Sara I. Cunha et al.
BLOOD (2011)
Effects of methimazole on the elimination of irinotecan
Jessica M. van der Bol et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
Dana D. Hu-Lowe et al.
CANCER RESEARCH (2011)
Blockade of TGF-β Signaling by the TGFβR-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma
Mengxian Zhang et al.
CANCER RESEARCH (2011)
EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
Virginie Poindessous et al.
CLINICAL CANCER RESEARCH (2011)
Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Roberta Rosa et al.
CLINICAL CANCER RESEARCH (2011)
Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Chung-Pu Wu et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer
Mirela Nadler-Milbauer et al.
JOURNAL OF DRUG TARGETING (2011)
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
E. F. Dunn et al.
ONCOGENE (2011)
Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
Alex A. Adjei et al.
ONCOLOGIST (2011)
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer
Gui-Fang Guo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
An epigenetic mechanism for capecitabine resistance in mesothelioma
K. V. Kosuri et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells
Kazuhito Sasaki et al.
BMC CANCER (2010)
Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells
Anne-Sophie Belanger et al.
BMC MOLECULAR BIOLOGY (2010)
The Epidermal Growth Factor Receptor Antibody Cetuximab Induces Autophagy in Cancer Cells by Downregulating HIF-1α and Bcl-2 and Activating the Beclin 1/hVps34 Complex
Xinqun Li et al.
CANCER RESEARCH (2010)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
J. Randolph Hecht et al.
CLINICAL CANCER RESEARCH (2010)
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
Mario Scartozzi et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer
Diane Lauren Reidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Autophagy: cellular and molecular mechanisms
Danielle Glick et al.
JOURNAL OF PATHOLOGY (2010)
Convergence between Wnt-β-catenin and EGFR signaling in cancer
Tianhui Hu et al.
MOLECULAR CANCER (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Therapeutic Targeting of Melanoma Cells Using Neural Stem Cells Expressing Carboxylesterase, a CPT-11 Activating Enzyme
Margarita Gutova et al.
CURRENT STEM CELL RESEARCH & THERAPY (2010)
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Mads Gyrd-Hansen et al.
NATURE REVIEWS CANCER (2010)
Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells
Jie Li et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro
Kate Connolly et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
S-1: a promising new oral fluoropyrimidine derivative
Muhammad Wasif Saif et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Inhibition of Transforming Growth Factor β Receptor I Kinase Blocks Hepatocellular Carcinoma Growth Through Neo-angiogenesis Regulation
Antonio Mazzocca et al.
HEPATOLOGY (2009)
Molecular Mechanisms of IFN-gamma to Up-Regulate MHC Class I Antigen Processing and Presentation
Fang Zhou
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance
Rita Humeniuk et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy
R. Soong et al.
ANNALS OF ONCOLOGY (2008)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells
Wan Seok Yang et al.
CHEMISTRY & BIOLOGY (2008)
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study
Howard S. Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan
J. Uchino et al.
CANCER GENE THERAPY (2008)
Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
Mara S. Lippa et al.
APOPTOSIS (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
Vincenzo Damiano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia
Jessica M. van der Bol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
Robert W. Robey et al.
MOLECULAR CANCER THERAPEUTICS (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Roles of epidermal growth factor family in the regulation of postnatal somatic growth
Cory J. Xian
ENDOCRINE REVIEWS (2007)
The Bcl-2 apoptotic switch in cancer development and therapy
J. M. Adams et al.
ONCOGENE (2007)
L-arginine availability regulates T-lymphocyte cell-cycle progression
Paulo C. Rodriguez et al.
BLOOD (2007)
Suppression of DPYD expression in RKO Cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression
Xue Zhang et al.
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE (2007)
The inhibitors of apoptosis (IAPs) as cancer targets
Allison M. Hunter et al.
APOPTOSIS (2007)
Wnt/β-catenin signaling in development and disease
Hans Clevers
CELL (2006)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis
Eric C. LaCasse et al.
CLINICAL CANCER RESEARCH (2006)
Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer
JF Gagnon et al.
CLINICAL CANCER RESEARCH (2006)
The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research
MM Gottesman et al.
FEBS LETTERS (2006)
Novel Toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors
V Damiano et al.
CLINICAL CANCER RESEARCH (2006)
Protoberberine alkaloids and their reversal activity of P-gp expressed multidrug resistance (MDR) from the rhizome of Coptis japonica Makino
Yong Deuk Min et al.
ARCHIVES OF PHARMACAL RESEARCH (2006)
Methylation of the DPYD promoter:: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients
HH Ezzeldin et al.
CLINICAL CANCER RESEARCH (2005)
The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation:: Influence of tumor site, type of mutation, and adjuvant treatment
A Russo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels et al.
CANCER CELL (2005)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11
D Oosterhoff et al.
BRITISH JOURNAL OF CANCER (2005)
Molecular mechanisms of drug resistance
DB Longley et al.
JOURNAL OF PATHOLOGY (2005)
Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells
SK Kuwada et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses
PC Rodriguez et al.
CANCER RESEARCH (2004)
The PIK3CA gene is mutated with high frequency in human breast cancers
KE Bachman et al.
CANCER BIOLOGY & THERAPY (2004)
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
F Innocenti et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma
Xiang-Tao Ma et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression
P Terheyden et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2003)
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
Y Xu et al.
ANNALS OF ONCOLOGY (2002)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells
T Takechi et al.
EUROPEAN JOURNAL OF CANCER (2002)
The roles of IFNγ in protection against tumor development and cancer immunoediting
H Ikeda et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
M Malet-Martino et al.
ONCOLOGIST (2002)
Role of BAX in the apoptotic response to anticancer agents
L Zhang et al.
SCIENCE (2000)
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells
MJ Jo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
